Pyrogens are fever causing substances after administering into the blood. The body ache and rise in body temperature are the notable reactions caused due to injection of unsafe pyrogens in the body. Monocyte activation testing determines the existence of pyrogen and endotoxin substances. The demand for pyrogen testing is currently not limited to the pharmaceutical companies and biological companies but is expanding among other end users too. The global monocyte activation tests market was valued approximately US$ 5.0 Mn in 2016 and is anticipated to register CAGR of over 14.0% from 2017 to 2025 to reach value of approximately US$ 19.0 Mn by 2025.
The global monocyte activation tests market is witnessing continuous innovations in test offerings and wide product portfolio of major as well as local manufacturers. The growth of the global monocyte activation tests market is mostly driven by increasing number of biotechnology and pharmaceutical companies globally, growing research and development investments and increasing new drug approvals.
Moreover, additional aspects such as increasing healthcare expenditure, Increase in new innovative drugs and launch of biological products, increase in public and regulatory concerns about product safety support the market growth. Additionally, a proposed ban on animal tests reducing the use of the rabbit pyrogen test is one of the key factors that driving the growth of monocyte activation tests. Increasing contract research organization in the Latin American and Asia Pacific regions coupled with developing healthcare industry in emerging economies define the future landscape of the monocyte activation tests market.
The global monocyte activation tests market has been categorized on the basis of product type, source, application, end users, and geography. Among product types, the reagent segment accounted for the largest market share in 2016. However, monocyte activation test kits segment is anticipated to grow at a higher growth rate during the forecast period.
Continuously rising adoption of superior-quality products newly introduced in the market are expected to drive the MAT kits segment during the forecast period. Among the sources, blood based segment accounted for the largest market share in 2016, blood-based MAT exhibits a natural human reaction to pyrogens and provides a better estimate of pyrogenic activity of preparations than the limulus amebocyte lysate (LAL) or rabbit pyrogen test (RPT). In term of application, medical devices segment accounted the largest market share in 2016.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=36041
Increasing number of medical devices in market demands for the pyrogen test before approval in the market, this drives the medical devices segment. In end user segment pharmaceutical industry segment accounted for the major share in 2016, while biotechnology industry is anticipated to grow at higher CAGR during the forecast period, owing to factors such as increase in number of research studies in biotech companies to launch various new products likely to increase use of monocyte activation tests kits and reagents.
The global monocyte activation tests market has been divided into five main regions: North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. In terms of revenue, North America is projected to be the dominant market for global monocyte activation tests market in 2016 with more than 30.0% market share owing to many of the leading players located in the region coupled with expanding research and development activities and rising health care awareness. The North America monocyte activation tests market is likely to expand at an average CAGR during the forecast period. Reagent product type segment is estimated to hold the highest share of the North America monocyte activation tests market in 2016. Asia Pacific is expected to be the rapidly developing markets in terms of CAGR during the forecast period.
The monocyte activation tests market in Europe is witnessing significant growth, increasing research activities in drug discovery and growing awareness about animal-free endotoxin detection are the key factors supporting the growth of the monocyte activation tests market in Europe. Rapidly growing medical devices, pharmaceutical, and biotechnology industry are primarily driving the growth of the global monocyte activation tests market. In addition, increasing government support and thereby increasing launch of new drugs is fueling the growth of the global monocyte activation tests market.
Key companies operating in the global monocyte activation tests market and profiled in the report include Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories International, Inc., Sanquin, Microcoat Biotechnologie GmbH, Becton, Dickinson and Company, SOLVIAS AG and Lonza Group.